😨☕️ CAFÉ, DEPRESIÓN Y ANSIEDAD 🚩🚩El consumo de 2-3 tazas de café al día se asocia: ⇩⇩Reducción de la ansiedad. ⇩⇩Reducción de la depresión. 🥇Café molido sin azúcar y café molido con leche son los que mejores resultados presentan.

Jaja mentira no es

Lobular breast cancer statistics, 2025 📊 ILC = 1 in 10 BCs ⬆️ +2.8%/yr 🧬 HR+/HER2–: 90% 💊 Chemoresistant & worse survival in advanced stage 🕵️‍♂️ Often missed, underdetected, undertreated 👉 Not just "ductal-lite". ILC deserves its own spotlight.. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

🎀 Less May Be More in Elderly Breast Cancer! New Swedish cohort study 🇸🇪 suggests post-lumpectomy RT can be safely omitted in select low-risk, ER⁺, T1N0 older women on endocrine therapy. 🧪 Study: Swedish Breast Cancer Group, n = 601 (median age 71) 🎯 Treatment: Lumpectomy

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer annalsofoncology.org/article/S0923-…

🧫 Liver Cirrhosis & Immune Status in #HepatocellularCarcinoma 🩺 Understanding cirrhosis progression & immune dysfunction 🩺 Correlation between immune microenvironment and HCC pathogenesis 🩺Guiding risk stratification & precision interventions 🔗 [oaepublish.com/articles/2394-…]

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… OncoAlert #RadOnc

Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial ➡️ doi.org/10.1093/bjs/zn… The difference in LRR between TNT and CRT mainly occurred in patients treated with

Enjoy! e-revna.com/index.php/edit…

Publish with us! We support #radonc.

STOPCAP at #ESMO26 Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS. Restricted to <5 bone or low volume mets on conventional imaging. No interaction with other patient/tumor characteristics.

We just published in The Lancet Oncology a very important paper regarding the new FDA guidance on overall survival assessment in cancer drug trials. Right in time for #ESMO25. Please do read. I promise you that you’ll learn something that’s applicable broadly. And follow along this

New in #practicalRO: Postmastectomy Radiation Therapy: An ASTRO/ASCO/SSO Clinical Practice Guideline. tinyurl.com/propmrt

The AlphaBet trial Peter Mac Cancer Centre The Lancet Oncology release today ESMO - Eur. Oncology #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future

In 1992 Peter Ratcliffe received this rejection letter from Nature. His findings were not "a sufficient advance in our understanding". 27 years later he won the Nobel Prize for the same discovery. Don't lose faith in the things you believe in.

New in #practicalRO: Long-Term Outcome of Stereotactically Designed Hypofractionated Image Guided Radiation Therapy in Large, Unresectable Hepatocellular Carcinoma.

A must-read review on non-clear cell RCC! JCO Oncology Practice 👉doi.org/10.1200/OP-25-… ASCO #Cancer #Oncology OncoAlert Pedro C Barata, MD MSc FACP

Prostate radiotherapy in PEACE-1: is the event worth the treatment? - Authors' reply - PubMed pubmed.ncbi.nlm.nih.gov/40683705/

ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025 = FIGO 2023 + molecular subtypes (POLEm, MMRd, NSMP, p53abn) ◽️Risk low < 8%, intermediate 8–14%, high-intermediate 15–24%, high ≥ 25% ◽️Test HER2 in serous/p53abn, ER in all